Short answer
Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the three months ended September 30, 2026.
Zymeworks Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the three months ended September 30, 2026
- Full financial details and management commentary contained in Exhibit 99.1, the attached press release
Item 7.01 · Regulation FD Disclosure
- Zymeworks identifies SEC filings, press releases, investor websites, conferences and social media as potential sources of material information
- Investors should monitor these channels for updates on product candidates, corporate developments and other market-sensitive disclosures
- Regulation FD strategy broadens disclosure distribution beyond formal SEC filings, increasing importance of company communications between filings
Item EX-99.1 · Exhibit EX-99.1
- 3Q revenue $256.5M vs $27.6M, driven by $250.0M Ziihera approval milestone from Jazz
- 2026 guidance raised: revenue $337M-$351M and Adjusted EBITDA $176M-$190M
- Ziihera first-line GEA approval expands royalties and delivered the $250M milestone, with up to $190M additional ex-U.S. milestones
- Roche ZW209 deal offers $55M upfront, $40M Phase 1b payment, up to $718M milestones, plus tiered royalties pending HSR clearance
- Theravance acquisition adds YUPELRI revenue and targets $13M-$15M annual overhead savings, but increased leverage and integration costs weigh on financial risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zymeworks Inc. 8-K filings
Get the next ZYME 8-K as it lands
Follow ZYME for push alerts, or ask the research agent what this filing means.